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The expression signatures in liver and adipose
tissue from obese Göttingen Minipigs reveal a
predisposition for healthy fat accumulation
Susanna Cirera1, Emirhan Taşöz1, Mette Juul Jacobsen1, Camilla Schumacher-Petersen1,
Berit Østergaard Christoffersen2, Rikke Kaae Kirk2, Trine Pagh Ludvigsen2, Henning Hvid2, Henrik Duelund Pedersen1,3,
Lisbeth Høier Olsen1 and Merete Fredholm 1
Abstract
Background: Model animals are valuable resources for dissecting basic aspects of the regulation of obesity and
metabolism. The translatability of results relies on understanding comparative aspects of molecular pathophysiology.
Several studies have shown that despite the presence of overt obesity and dyslipidemia in the pig key human
pathological hepatic findings such as hepatocellular ballooning and abundant steatosis are lacking in the model.
Objectives: The aim of this study was to elucidate why these histopathological characteristics did not occur in a high
fat, fructose and cholesterol (FFC) diet-induced obese Göttingen Minipig model.
Methods: High-throughput expression profiling of more than 90 metabolically relevant genes was performed in liver,
subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) of male minipigs diet fed: standard chow (SD, n=
7); FFC diet (n= 14); FFC diet in streptozotocin-induced diabetic pigs (FFCDIA, n= 8). Moreover, histopathological
assessment of SAT and VAT was performed.
Results: 12, 4 and 1 genes were highly significantly differentially expressed in liver, SAT and VAT when comparing the
FFC and SD groups whereas the corresponding numbers were 15, 2, and 1 when comparing the FFCDIA and SD
groups. Although the minipigs in both FFC groups developed sever obesity and dyslipidemia, the insulin-signaling
pathways were not affected. Notably, four genes involved in lipid acquisition and removal, were highly deregulated in
the liver: PPARG, LPL, CD36 and FABP4. These genes have been reported to play a major role in promoting hepatic
steatosis in rodents and humans. Since very little macrophage-associated pro-inflammatory response was detected in
the adipose tissues the expansion appears to have no adverse impact on adipose tissue metabolism.
Conclusion: The study shows that morbidly obese Göttingen Minipigs are protected against many of the metabolic
and hepatic abnormalities associated with obesity due to a remarkable ability to expand the adipose compartments to
accommodate excess calories.
Introduction
Obesity has been associated with a strong predisposition
to metabolic syndrome (MS) and Type 2 diabetes mellitus
(T2DM). In turn, these diseases are strongly associated
with non-alcoholic fatty liver disease (NAFLD) and non-
alcoholic steatohepatitis (NASH). These conditions are
characterized by a build-up of fat in the liver (hepatic
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steatosis), inflammation, fibrosis, and cell damage, and in
extreme cases NASH can lead to liver cirrhosis with
hepatic failure and/or hepatocellular carcinoma (HCC)1.
The molecular events underlying the development of
NAFLD/NASH are poorly understood, however, it has
been shown that there is a greater impact of metabolic
health on the development of NAFLD, as compared to
obesity per se2. One determinant of metabolic health is
the mechanism by which adipose tissue depots expand3,4.
This has led to the adipose tissue expandability hypothesis
stating that the capacity of an individual to expand the fat
mass to store lipid is a more important determinant of
obesity-associated metabolic problems than the absolute
amount of adipose tissue5. The expandability hypothesis
predicts that some individuals tend to have a bigger
capacity for adipose tissue storage and adaptation to
excess energy while remaining metabolically healthy
(metabolically healthy obese (MHO)). This capacity is
most likely determined by genetic and epigenetic factors6.
Different breeds of minipigs, including Bama, Ossabaw
and Göttingen have been used as models for MS and
obesity, and some of them specifically as models for liver
disease in humans. In these studies, different Western
diets and atherogenic diets have been shown to have
potential for producing liver fibrosis, systemic inflamma-
tion, insulin resistance and steatohepatitis7–13. In general,
however, these models only show very limited and pri-
marily microvesicular hepatic steatosis as opposed to the
more extensive macrovesicular type observed in humans.
This indicates that inflammation and fibrosis are driven
by other factors than steatosis in these porcine models.
We have previously provided evidence of genetic pre-
disposition for an MHO-like phenotype in Göttingen
Minipigs14. In this study, we have performed high-
throughput qPCR on genes of relevance for metabolism
in liver, subcutaneous adipose (SAT) and visceral adipose
tissues (VAT) to characterize the transcriptional changes
underlying the alterations observed in these tissues in
Göttingen Minipigs fed chow, FFC diet, or FFC diet on a
background of streptozotocin-induced diabetes for
13 months. The minipigs in the two groups fed the FFC
diet were morbidly obese and dyslipidemic, however, key
human pathological hepatic findings characterizing
NAFLD/NASH were lacking. Our aim was to elucidate
the molecular components underlying the histopatholo-
gical changes observed in the model, and to explain the
reason for the limited hepatic steatosis that characterizes
the porcine models of metabolic syndrome and NASH.
Materials and methods
Animals
Castrated male Göttingen Minipigs (Ellegaard Gottin-
gen Minipigs A/S, Dalmose, Denmark) (n= 84 in total)
aged 6–7 months were weight stratified and distributed
into six treatment groups and fed once daily for thirteen
months. Of these, 29 pigs distributed in three groups were
studied in this study. The included groups were: a lean
control pigs (SD, N= 7) fed standard diet (Mini-pig, SDS,
UK); a group fed high fat/fructose/cholesterol diet (FFC,
N= 14) with (2%) cholesterol (5B4L) for the first five
months and changed to a similar diet with 1% cholesterol
(9G4U) for the next eight months (Test diet®, Missouri,
USA); a streptozotocin-induced diabetic group (FFCDIA,
N= 8) fed a high fat/fructose/cholesterol (1%) diet
throughout the study (9G4U). Data from the same 29 pigs
have been included in parallel studies focusing on histo-
logical changes in the liver tissue and myocardial chan-
ges12,15. Basic phenotypic and metabolic characteristics,
measured as described in12 are reported in Table 1.
In the diabetic group (FFCDIA) type 1-like diabetes was
induced with streptozotocin (as described in ref. 12).
Diabetic pigs were treated subcutaneously once daily with
long acting insulin (Lantus®, Sanofi A/S, Denmark) in
order to maintain morning fasting blood glucose around
15mM.
All animals were fasted overnight before euthanasia by
exsanguination in deep general anesthesia (mixture of
zolazepam, tiletamine, ketamine, xylazin and butorpha-
nol). Samples from liver (left medial lobe), subcutaneous
adipose (SAT) and visceral adipose (VAT) tissues were
collected, snap frozen in liquid nitrogen and kept at
−80 °C for expression studies.
RNA isolation
Fifty miligram of frozen tissue were used for RNA iso-
lation using the Tri® Reagent protocol (MRC Gene,
Cincinnati, OH 45212 USA). Briefly, the tissue was
homogenized in 2ml Tri® Reagent using M-tubes in a
gentleMACS™ Octo Dissociator machine (Miltenyi Bio-
tec, Bergisch Gladbach, Germany) and processed
according to the manufacturer’s instructions. RNA sam-
ples were subsequently DNAse treated using RNeasy
MinElute Cleanup kit (Qiagen, GmbH, Germany). RNA
from adipose tissues were isolated from 20–180mg tissue
using the method described by ref. 16 including DNAse I
treatment.
Concentration and purity of the RNA samples were
measured on a Nanodrop ND-1000 spectrophotometer
(NanoDrop technologies, Wilmington, USA). RNA
integrity was assessed on an Experion machine using the
RNA stdSens kit. All liver samples had an RNA-quality
index (RQI) between 8.10 and 9.70 (average= 9.25 ±
0.36). Adipose tissue samples with an RQI between 6.5
and 10 were included for further processing (average=
8.4 ± 0.68 for SAT and average= 8.2 ± 0.92 for VAT). One
SAT sample from the FFCDIA group and three VAT
samples (2 from the SD and 1 the FCCDIA group) were
excluded from the study due to low RQI.
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cDNA synthesis
Two replicates of cDNA were prepared from each RNA
sample using 500 ng of DNAse treated RNA from liver
tissue samples and 100 ng of DNAse treated RNA from
adipose tissue samples. Briefly 0.5 μl Improm-IITM reverse
transcriptase (Promega, Madison, USA), 0.25 μg 1:3 Oli-
godT/Random primers, 2 μl 5× ImProm-II buffer, 10 units
RNasin Ribonuclease inhibitor (Promega, Madison, USA),
2.5 mMMgCl2 and 2mM dNTP were mixed with RNA in
a final reaction volume of 10 μl. Reactions were incubated
for 5 min at room temperature, 1 h at 42 °C and 15 min
inactivation at 70 °C. Two negative controls were made
for each tissue with no reverse transcriptase added (-RT
control). The liver cDNA samples were diluted 1:16 and
the adipose cDNA samples were diluted 1:8 prior to qPCR
and stored at −80 °C until use.
Primer design
The genes included in this study were selected from an
in house obesity panel used in other projects (e.g., ref. 17)
supplemented by additional genes of importance to liver
and adipose tissue metabolism (see Table S1). Four
reference genes selected according to ref. 18 were included
for normalization for each tissue. Primers were designed
using the tool “Pick Primers” in PubMed to amplify a
product in the range of 100 nucleotides, and if possible,
were designed to span a large intron. Primer sequences,
gene names and the respective tissues profiled are avail-
able in Table S1.
qPCR
High-throughput qPCR was performed on the Biomark
HD system (Fluidigm Corporation, California, USA) using
four 96.96 IFC chips. The diluted cDNA was used for pre-
amplification (15 cycles for liver and SAT samples and 14
cycles for VAT samples) using TaqMan PreAmp Master
Mix (Life Technologies, Nærum, Denmark). Subsequent
cleanup with Exonuclease I (New England BioLabs, Her-
lev, Denmark) was performed according to the Fluidigm
protocol (Fluidigm PN 100–5875 C1). A single mod-
ification to the standard protocol was made: we used
250 nM primer concentrations in the primer pool. Exo-
nuclease cleaned liver and SAT cDNA were diluted 5x
and VAT cDNA was diluted 10× before running the
qPCR reactions using SsoFastTM EvaGreen® Supermix
with Low ROX (Bio-Rad Laboratories, Copenhagen,
Denmark) according to the manufacturer’s instructions
(PN 100–9792 B1) with the modification of using primer
concentrations of 5 μM. A standard curve was established
for each tissue using a dilution serial of a pool of pre-
amplified cDNA samples. Data was obtained using the
associated software. A few genes (TGFB1, LDAH, and
BCL2 for liver and PPARG and CD36 for VAT) had sev-
eral missing values in the Fluidigme qPCR study and were
therfore re-run on the MxPro (Stratagene) platform. In
addition, four of the deregulated genes (CD36, FABP4,
LPL, and PPARG) were analyzed on the Mx3005P plat-
form in all three tissues in order to make a direct com-
parison of expression level between tissues. In this study two
additional primer sets were included for PPARG in order to
amplify isoform 1 and isoform 2 separately (see Table S1).
For all genes run on the Mx3005P platform, QuantiFast
SYBRGreen master mix (Qiagen, GmbH, Germany) was
used according to the manufacturer’s protocol.
qPCR data processing and statistical analysis
qPCR raw data was pre-processed using Genex 6 Pro
software (MultiD Analyses AB, Götteborg, Sweden).
Table 1 Phenotypic and metabolic characteristics of the minipigs.
Diet group SD (n= 7) FFC (n= 14) FFCDIA (n= 8) Over all p-value
BW (kg) 39 (38; 41) 78 (69; 81)a 60 (54; 64)ab <.0001˄
LW (g) 485 (458; 564) 1732 (1067; 2219)a 2077 (1478; 2439)a <.0001˄
TBF% 28 (24; 31) 64 (61; 68)a 55 (53; 56)ab <.0001
VAT (g) 510 (462–543) 2326 (1645–2946)a 1335(1032–1922)a,b <0001^^
TG in liver (mg/g) 12.6 (8.1–14.4) 15.0 (13.3–17.7) 19.6 (13.6–26.7)a NS^
Plasma TC# (mmol/L) 1.70 (1.64; 2.18) 11.94 (11,00; 13.18)a 18.91 (16.91; 27.00)ab <0.0001˄
Plasma TG# (mmol/L) 0.34 (0.29; 0.35) 0.63 (0.54; 0,88)a 1.45 (0.57; 1.72)ab 0.0002˄
Plasma GLU# (mmol/L) 3.48 (3.32; 3.67) 3.72 (3.60; 3.83) 15.1 (14.67; 15.45)ab <.0001˄
Results are presented as median and 25% and 75% quartiles; #n= 6 for SD, n= 13 for FFC, n= 6 for FFCDIA due to catheter failure;
BW body weight, LW liver weight, TBF Total body fat, VAT Visceral adipose tissue, TC total cholesterol, TG triglycerides, GLU glucose.
˄Transformed;
^^Non-parametric test;
aSignificantly different from SD;
bSignificantly different from FFC. Data except VAT have been presented previously (Andreasen et al., 2018; Schumacher-Petersen et al., 2019).
Cirera et al. Nutrition and Diabetes            (2020) 10:9 Page 3 of 12
Nutrition and Diabetes
Briefly, data was corrected according to PCR efficiency
(PCR efficiencies between 80–110% were accepted), data
was normalized to the two most stable reference genes
(TBP and ACTB in liver and SAT; TBP and YWHAZ in
VAT). Subsequently, technical cDNA replicates were
averaged and relative expression was calculated by scaling
data with the lowest expressed sample for each assay.
Next, data was log2 transformed to achieve normal dis-
tribution before statistical analysis. Multiple test correc-
tion was applied to the analysis and statistical significance
threshold was set at P < 0.0006 (according to the Dunn-
Bonferroni correction for multiple testing). Comparisons
between the different experimental groups were per-
formed using t-test and fold-changes (FC) and P values
under < 0.05 were reported (Tables 1, 2, 3).
For the metabolic and physical measurements, group
differences were evaluated using ANOVA and post hoc t-
test. Parameters were transformed if they did not meet
model requirements. Kruskal-Wallis test with Wilcoxon
Rank-sum post hoc test (non parametric) was used if
transformed data did not meet model requirement even
after transformation. Data and results are presented as
median and 25% and 75% quartiles. Values of P < 0.05
were considered statistically significant.
Pearson correlation analyses were performed on gene
expression data for CD36, FABP4, LPL, and PPARG in the
liver tissue and relevant metabolic/physical measurements
using Rstudio19. For the Pearson correlation analysis, log2
transformed expression values were further processed
using R scripts, together with the Göttingen Minipig
physiological measurements
Histology
VAT and SAT tissue samples were fixed in formalin and
subsequently embedded in paraffin following standard
procedures. Sections of 3 µm thickness were cut from
SAT and VAT and routinely stained with hematoxylin
and eosin (HE) as described previously12.
Results
The expression profiles of 96 genes in liver, and 98
genes in SAT and VAT samples were assayed on the
Fluidigm high-throughput qPCR platform and/or on the
Mx3005P 96-format platform (see Table S1 for details).
Since the PPARG transcript generates two isoforms
(PPARG1 and PPARG2) three primer pairs were used for
the amplification of the transcripts. The PPARG primers
amplify both isoforms whereas PPARG1 and PPARG2
amplify the respective isoforms. The total number of
successful assays (including reference genes) was: 82 in
liver, 86 in SAT and 90 in VAT. Fourteen assays in liver,
12 in SAT and eight in VAT failed due to one of the
following reasons: unspecific amplification as evidenced
by more than one peak in the melting curve; expression
levels under the limit of detection; qPCR efficiencies out
of range (<80% or >110%) or no amplification. Raw Cq
values for all successfully profiled genes in liver, SAT and
VAT are presented in Tables S2, S3, and S4 respectively.
All differentially expressed genes for which P < 0.05 are
listed in Tables 2, 3, 4. In the following only differentially
expressed genes with fold changes (FC) > 2 or <−1.5 and
multiple testing-corrected P values < 0.0006 will be dis-
cussed together with a few genes of interest having dif-
ferential expression with P < 0.05.
Differential expression in liver
As shown in Table 2, when looking at gene expression
in the liver of animals subjected to the FFC diet vs. the SD
diet 12 genes showed significant P values after correction
for multiple testing with FC of >2 or <−1.5. Four of these
genes were upregulated (LPL (FC= 172.23), CD68 (FC=
5.17), PPARG (FC= 19.08) and CD36 (FC= 3.36), and
eight were downregulated (KLB (FC=−22.24), HMGCR
(FC=−13.36), FDFT1 (FC=−6.31), LDLR (FC=−5.92),
SOD1 (FC=−1.76), STAT3 (FC=−1.92), PPARGC1A
(FC=−2.38) and MTTP (FC=−1.73)). In addition, 33
genes were deregulated with P < 0.05 and of those, 21
genes had FC > 2 or >−1.5; among these FABP4 with
FC= 2.56 (see Table 2). A total of 9 out of the 12 genes
deregulated between the FFC and the SD groups were also
deregulated between the FFCDIA and the SD groups. The
differential expression between these two groups was,
however, much higher for some of the genes, i.e., FC=
308.25 for LPL; FC= 35.56 for PPARG; FC=−16.30 for
FDT1; FC=−36.89 for KLB; FC=−6.30 for CD36; and
FC= 11.8 for FABP4 indicating that induction of diabetes
had additional impact on perturbation of liver metabolism
compared to the FFC diet alone. This is further supported
by the fact that additional genes obtained multiple testing
corrected P values < 0.0006 (AGT, TLR4, FABP4, MMP9,
GHR, and GCKR) (see Table 2). Generally, the insulin-
signaling pathways were not affected neither in the FFC
diet group nor in the FFCDIA diet group as documented
by an unchanged level of transcription of e.g., IDE,
INSIG1, INSIG2, IGF1, IGF2, IGFBP2, and IRS1. Only
IRS2 was slightly downregulated in both the FFC and the
FFCDIA groups (FC=−1.73 and −1.94, respectively)
and INSR was slightly downregulated in the FFC group.
(FC=−1.32).
Differential expression in adipose tissues
As shown in Table 3a, b the fold changes of the dif-
ferentially expressed genes were much lower in the adi-
pose tissues relative to the differential expression
observed in liver. There was only four (PN-1, EBF2,
ABCG1, IL6) and two (ABCG1, IL6) genes with FC > 2
or <−1.5 in SAT when comparing FFC vs. SD and FFDDiA
vs. SD, respectively with P values passing multiple testing.
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In VAT only one gene with FC > 2 or <−1.5 and P values
passing multiple testing was seen in the FFC vs. SD and
FFDDIA vs. SD comparisons (LDLR and RPS29
respectively). SAT presented a higher number of differ-
entially expressed genes compared to VAT in response to
both the FFC and FFCDIA diet. A common trend in the
Table 2 Differential expression in the liver.
FFC vs. SD FFCDIA vs. SD
Genes FC P value Genes FC P value
LPL 172.23 1.00E−08 LPL 308.25 1.00E−08
CD68 5.17 1.00E−08 CD68 6.30 1.00E−08
PPARG 19.08 1.60E−08 PPARG 35.56 1.70E−07
KLB −22.24 7.69E−06 FDFT1 −16.30 5.04E−07
HMGCR −13.36 2.28E−05 KLB −36.89 3.74E−06
FDFT1 −6.31 3.76E−05 CD36 6.30 3.94E−06
LDLR −5.92 3.82E−05 SOD1 −2.02 1.49E−05
SOD1 −1.76 5.02E−05 AGT −2.80 2.45E−05
CD36 3.36 8.79E−05 TLR4 2.89 3.06E−05
STAT3 −1.92 0.000371384 HMGCR −14.26 4.28E−05
PPARGC1A −2.38 0.000488187 FABP4 11.81 9.91E−05
MTTP −1.73 0.00052084 MMP9 7.80 0.000166417
FABP4 2.56 0.001362823 GHR −2.65 0.000416258
APOB −1.57 0.001397134 LDLR −4.38 0.000488511
TLR4 1.89 0.001562476 GCKR −2.15 0.00056221
MMP9 6.02 0.001698359 TM6SF2 −1.53 0.00061856
GCKR −1.66 0.00214768 SREBF1 3.65 0.001299769
TM6SF2 −1.31 0.002397241 PNPLA3 −5.26 0.001575959
AGT −1.69 0.002518911 SCARB1 −1.59 0.001871992
BCL2 2.14 0.002743402 LCAT −3.00 0.00205255
CCL5 1.58 0.003410192 LPIN1 −2.84 0.002087286
RBP4 −1.70 0.003613226 IL1B −3.60 0.002132827
IRS2 −1.73 0.003906641 RORA −2.01 0.002903257
SREBF1 2.60 0.004448657 MBOAT7 −1.44 0.002998874
PCSK9 −2.57 0.004967516 IRS2 −1.94 0.003022747
NR1I2 −1.48 0.004979217 STAT3 −2.01 0.003147541
GLUT2 −1.81 0.005005041 RBP4 −1.79 0.004035618
GNMT −2.19 0.005392574 DGAT2 −1.73 0.004160409
APOC3 −1.69 0.006004771 BCL2 2.63 0.004241219
ACACA −1.61 0.006809141 TNF −2.96 0.005578895
MBOAT7 −1.30 0.007224475 PPARGC1A −2.63 0.005607015
IGFBP2 −1.86 0.008639175 NR1I2 −1.49 0.006846227
LPIN1 −2.02 0.010294258 APOA4 6.29 0.007329076
INSIG1 −2.80 0.010494044 LEPR_01 2.55 0.008111383
MCM5 1.67 0.018981469 APOA1 −1.65 0.008870278
RORA −1.63 0.021173678 FGFR4 −1.70 0.009941781
SCARB1 −1.38 0.021396819 APOC3 −1.66 0.014547442
DGAT2 −1.70 0.024872243 PCSK9 −2.67 0.015028567
SCD 1.80 0.025667474 TGFB1 1.72 0.016112059
COL1A1 2.49 0.028417769 MTTP −1.47 0.017813835
SCAP −1.28 0.032446191 APOB −1.40 0.022577003
TIMP1 1.87 0.032793714 GLUT2 −1.84 0.024123063
GHR −1.82 0.034630017 CTGF 2.16 0.035424956
INSR −1.32 0.035708148 FOXO1 −1.49 0.043783298
LDAH −1.37 0.04920525 SCD 1.96 0.043939123
COL1A1 2.56 0.045340498
FC fold change; P-values: all genes with p < 0.05 are listed (ranked according to P-values): genes highlighted in bold have FC > 2 or < −1.5 and multiple testing-
corrected P values <0.0006; A positive FC indicates that the gene is upregulated in the FFC and FFCDIA groups, respectively, and a negative FC indicates that the gene
is downregulated in the FFC and FFCDIA groups, respectively.
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Table 3 Differential expression in SAT and VAT.
(a) SAT
FFC vs. SD FFCDIA vs. SD
Genes FC P value Genes FC P value
PN-1 2.05 3.20E−05 ABCG1 3.89 0.00011538
EBF2 −1.69 0.00010886 IL6 2.67 0.00035439
ABCG1 2.64 0.00022215 ABCA1 2.63 0.00067173
IL6 2.87 0.00043198 PN-1 2.77 0.00137394
GNAS −1.57 0.00070595 MYC 1.52 0.0089967
SMPDL3A 3.03 0.00136871 SMPDL3A 2.98 0.01752013
FADS1 −2.18 0.00517238 ISLR −1.82 0.02213799
ISLR −2.23 0.00629454 ADCY5 1.74 0.02372845
ELOVL4 −2.00 0.01003605 GLUT4 −2.27 0.02893844
LEP 2.27 0.01139943 PON1 3.42 0.03258829
SP1 −1.59 0.0206303 SMAD6 1.48 0.03903247
DGAT2 −1.94 0.0210936 CD36 1.49 0.04384441
GLUT4 −2.57 0.02112195
CXCR4 2.06 0.02381762
MYC 1.62 0.02602224
PELI2 −1.42 0.02939702
HPRT1 6.24 0.03237427
CD36 1.37 0.03572498
DICER1 −1.78 0.03598225
LDLR −1.76 0.03737362
LCN2 (NGAL) −1.89 0.03992909
(b) VAT
FFC vs. SD FFCDIA vs. SD
Genes FC P value Genes FC P value
LDLR −2.17 0.00053665 RPS29 −2.28 5.88E−07
RPS29 −1.42 0.00282892 ABCA1 2.27 0.00151131
ABCA1 2.09 0.00375619 LDLR −1.96 0.01065563
TLR4 1.62 0.00451224 ABCG1 2.44 0.01258091
ACTB 1.54 0.01270316 IRS1 1.52 0.02980169
LITAF 1.25 0.01489724 LEPR −4.24 0.03295196
LSS −1.81 0.02886919
FAS −1.53 0.03170324
TGFB1 1.50 0.03959778
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two adipose tissues is that genes involved in lipid home-
ostasis are upregulated. I.e., ABCG1 in SAT (FC= 2.64 in
FFC vs. SD; FC= 3.89 in FFCDIA vs. SD); ABCA1 in SAT
(FC= 2.63 in FFCDIA vs. SD), and in VAT (FC= 2.09 in
FFC vs. SD; FC= 2.27 in FFCDIA vs. SD). Furthermore,
IL6 is upregulated in SAT (FC= 2.87 and FC= 2.67 in
FFC vs. SD and FFCDIA vs. SD, respectively).
Relative expression of selected genes in liver, SAT, and VAT
The expression of PPARG and its target genes (FABP4,
LPL, and CD36) were unchanged in SAT and VAT, but
highly differentially expressed in the liver (see Tables 2, 3, 4
and Tables S2, S3, S4). To compare the relative expression
levels between liver, SAT, and VAT the four genes were
assayed using the Mx3005P 96-format platform. The
expression levels of the genes in the liver from the SD
group of pigs were used as baseline. All three primer pairs
amplifying the isoforms of PPARG were included. Both
PPARG isoforms (PPARG1 and PPARG2) were expressed
in the three tissues. PPARG1 was slightly, but not sig-
nificantly, higher expressed in the liver compared to
PPARG2, whereas PPARG2 was slightly, but not sig-
nificantly, higher expressed compared to PPARG1 in SAT
and VAT (see Table S5). As illustrated in Fig. 1, CD36,
FABP4, and LPL were, as expected, expressed at a much
higher level in the adipose tissues whereas PPARG
expression in the liver of the FFC and FFCDIA groups were
comparable to the expression in the adipose tissues.
Correlation between adipose tissue expansion and
expression of selected genes in liver
A Pearson correlation analysis was performed to
investigate the possible association between expression of
PPARG and its target genes in the liver and increasing fat
deposition.
As seen in Table 4, the expansion of body fat and
visceral fat were significantly correlated (r= 0.81, p <
0.00001). Furthermore, expression levels of PPARG, LPL,
and CD36 were significantly correlated (p < 0.00001, p <
0.00001, and p < 0.0001, respectively) with total body fat
(r= 0.76, 0.81, and 0.67, respectively), whereas, only LPL
expression was moderately correlated with VAT (r= 0.6,
P < 0.001). Expression of the four genes was correlated
with highly significant correlation between PPARG, LPL
and CD36 (r > 0.9; P < 0.00001), and moderately sig-
nificantly correlation with FABP4 (r > 0.6, P < 0.001). As
expected no correlation was found between any of the
parameters and TG in liver.
Histopatholology and expression of pro-inflammatory
cytokines
Histopathological examination of sections from SAT
and VAT revealed no increase in macrophage infiltration
in the adipose tissues from the pigs subjected to the FFCTa
b
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diet relative to the pigs on the SD diet and Crown-like
structures were not observed (see Fig. 2). These findings
are supported by the expression profiles of the tissues,
that is, of the pro-inflammatory transcripts examined
(IL18, IL1B, IL6, TLR4, and TNF) only IL6, was upregu-
lated in SAT (FC= 2.86 and 2.67 in FFC vs. SD and
FFCDia vs. SD, respectively) whereas none of them were
upregulated in VAT.
Discussion
In this study we have profiled expression of genes of
relevance for metabolism in liver, subcutaneous adipose
(SAT) and visceral adipose tissues (VAT) to characterize a
Göttingen Minipig model of metabolic syndrome
and NASH.
As shown in Table 1, the FFC and FFCDIA groups
developed obesity with high body weight, high total body
fat % and dyslipidemia (i.e., increased triglyceride (TG)
and total cholesterol (TC) levels in plasma)12. In the study
by ref. 12, it was also shown that the FFC diet resulted in
development of hepatomegaly with hepatic fibrosis,
inflammation, cytoplasmic alterations, and increased
content of cholesterol, whereas no difference in trigly-
ceride content in the liver was found. Thus, hallmarks of
human NAFLD/NASH like severe steatosis and hepato-
cellular ballooning were lacking. Inducing diabetes on top
of the FFC diet did not exacerbate the histopathological
findings compared to the FFC diet12. Both the histo-
pathological findings and the results of the expression
studies clearly document that the FFC diet challenged
the metabolism in the liver. That diet rather than obesity
per se is the driving factor is supported by a previous
study in which hepatic differential expression between
Göttingen Minipigs fed standard minipig chow restric-
tively (lean controls) and Göttingen Minipigs fed the
same diet ad libitum (obese) was studied20. Although,
these treatments resulted in an obese group obtaining
roughly the same body weight as the FFC diet groups
included in this study, liver metabolism was far from
affected at the level documented here, indicating that the
diet components play a more important role than obesity
per se.
The increased inflammation observed in the liver in the
FFC and FFCDIA groups
12 was reflected in the expression
study, i.e., both the CD68 and TLR4 transcripts were
upregulated (the latter only in the FFCDIA group). It is
however noteworthy that staining with allograft inflam-
matory factor-1 (IBA1) only revealed moderate infiltration
of macrophages in the liver of the animals subjected to the
FFC diet12 perhaps explaining why in this study none of
the transcripts representing pro-inflammatory cytokines
(e.g., TNF, IL1B, IL18, IL6) were upregulated in the liver of
these animals. The increased content of collagen in liver
detected in the precious study12 is in concordance with
the increased expression of the MMP9 transcript which
encodes a protein that can cleave different types of
collagen.
Abundant hepatic steatosis, which is lacking in our
model, arises from an imbalance between triglyceride
acquisition and removal. In particular, four of the genes
that were upregulated in the liver have been reported to
play an important role in this context: PPARG, and three
of its target genes, i.e., LPL and CD36, and FABP4. Under
normal physiological conditions these genes are expressed
almost exclusively in adipose tissues in human and
mouse. In human studies the two isoforms of PPARG
have been shown to have different tissue distribution, i.e.,
PPARG1 is expressed in a wide variety of tissues, while
PPARG2 is mainly expressed in adipose tissues (reviewed
by ref. 21). In this study, we have shown that the two
isoforms are expressed at almost the same level in the FFC
and FFCDIA groups of pigs in both liver, SAT and VAT.
Both isoforms are lipogenic transcription factors that
function as inducers of adipocyte differentiation and
several lines of evidence suggest that PPARG activation
causes insulin sensitization in adipocytes (e.g., ref. 22,23).
The implications of an increased expression level of
PPARG in liver are less well documented. It has, however,
been shown that PPARG expression is elevated in the liver
of mice that develop fatty liver24, and PPARG has been
Fig. 1 Comparison of the relative expression of CD36, FABP4, LPL and PPARG in the liver from SD, FFC, and FFCDIA fed pigs, and in SAT and
VAT from SD fed pigs. The relative expression is provided in fold change and compared for each of the mentioned genes using the colour scheme
shown in the right hand top corner of the figure.
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reported to play a major role in promoting hepatic stea-
tosis in mice25. Both PPARG1 and PPARG2 also appear to
be upregulated in liver during the pathogenesis of NAFLD
in humans26. The increased expression of FABP4, CD36,
and LPL suggests increased fatty acid uptake, transport,
and metabolism in the livers of the FFC diet fed pigs.
FABP4 expression in liver has been shown to be sig-
nificantly elevated in mouse models of obesity-promoted
hepatocellular carcinoma and in patients with underlying
hepatic steatosis resulting from NAFLD27. Also, increased
expression of CD36 in the liver has been shown to occur
in response to diets rich in fatty acids, and this appears to
increase hepatic fatty acid uptake and exacerbates both
hepatic storage and secretion of triglyceride28. LPL plays a
critical role in regulating lipid metabolism and tissue-
specific effects are still being explored. Tissue specific
overexpression of LPL in skeletal muscle and liver in mice
has been reported to increased cellular stores of trigly-
cerides leading to insulin resistance29. Contrasting, a more
recent study in mice has shown that hepatic LPL is
involved in the regulation of plasma LPL activity and lipid
homeostasis30. Our results show that Göttingen Minipigs
do not develop abundant hepatic steatosis in spite of the
significantly increased expression of PPARG, FABP4,
CD36, and LPL in the liver. Thus, it might be speculated
that the ectopic expression of these genes are con-
sequences of high fat diet/obesity rather than the cause of
development of steatosis in the liver. We cannot rule out
that longer term FFC diet treatment/obesity might lead to
adverse metabolic responses. Still, abundant steatosis is
not an immediate outcome of the highly increased
expression level of PPARG, FABP4, CD36, and LPL in the
Fig. 2 Examples of adipocytes in SAT and VAT from representative pigs. a (SAT) and b (VAT) from a pig subjected to the SD diet; c (SAT) and d
(VAT) from a pig subjected to the FFCDia diet; e (SAT) and f (VAT) from a pig subjected to the FFC diet. Scale bar 500 µm. Hematoxylin and eosin
staining.
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liver of the severly obese minipigs. Conversely, since
PPARG and LPL expression in liver is significantly cor-
related with the amount of body fat (see Table 4) the
ectopic expression of the genes might have an influence
on the repartitioning of lipid from liver to adipose tissues.
This is also in keeping with the fact that the liver in pigs,
in contrast to humans and rodents, is not the primary site
of de novo lipogenesis31.
The ability of the Göttingen Minipigs to sustain the diet
challenges is also reflected in differential regulation of
genes involved in cholesterol biosynthesis in the liver. I.e.
HMGCR and FDFT1 are deregulated with a highly nega-
tive FC in the liver. Both genes are key regulators of
cholesterol biosynthesis and the observed downregulation
can most likely be explained by the abundance of cho-
lesterol in the diet. KLB is also deregulated with a highly
negative FC. KLB contributes to repression of CYP7A1—a
rate limiting enzyme in the bile acid biosynthesis pathway
that converts cholesterol into bile acids32. Thus, the
deregulation of the genes involved in cholesterol bio-
synthesis appears to assist in rectifying the diet-induced
increase in cholesterol through conversion of cholesterol
into bile acids.
As seen in Table 1, both body fat and visceral fat con-
tent were highly significantly increased in the FFC diet fed
groups, nevertheless, metabolism in the adipose tissues
was not affected to a great extent, although more so in
SAT compared to VAT. It is generally accepted that
metabolism differs between SAT and VAT, and that
excess VAT is unhealthier than excess SAT (e.g., ref. 33).
The increased expression of IL6 in the fat tissues is an
indication of low-grade inflammation; however, adipo-
genesis does not seem to be severely adversely affected by
the FFC diet neither in SAT nor in VAT. I.e., none of the
insulin sensitizing (e.g., ADIPOQ) or resistance genes (e.g.,
TNF) were perturbed. Rather, mainly genes involved in
lipid and cholesterol homeostasis (ABCA1, ABCG1) were
upregulated in these tissues. Lipid metabolism in the fat
tissue is supported by the high unchanged expression
level of PPARG, FABP4, CD36, and LPL in these tissues
(se Tables S2, S3, S4 and Fig. 1). Although both adipose
tissue compartments were substantially expanded in the
groups on the FFC diet, the highly significant correlation
between body fat and expression of PPARG, LPL, and
CD36 in the liver indicates, as previously mentioned, that
ectopic expression of these genes supports adipogenesis/
lipogenesis in body fat compartments rather than in the
liver. In contrast, obese human subjects with a high
degree of metabolic endotoxemia have been shown to
have lower expression of key genes for adipose tissue
function and lipogenesis (SREBP1, FABP4, FASN, and
LEP), but higher expression of inflammatory genes in
VAT and SAT34. In contrast to this, the only pro-
inflammatory cytokine upregulated in the obese
Göttingen Minipigs was IL6, which was upregulated in
SAT but not in VAT. This is supported by the histo-
pathological examinations which did not reveal an
increase in macrophage infiltration in SAT and VAT in
the obese pigs (see Fig. 2). Also, in contrast to our find-
ings, the expression of PPARG has been shown to be
significantly downregulated in SAT in severly obese
women35. Thus, our study shows that Göttingen Minipigs
are able to maintain fatty acid synthesis, and expand
the fat compartments without compromising adipose
tissue metabolism. Our results support the notion that the
capacity to expand fat mass to store lipids is a more
important determinant of obesity-associated metabolic
problems than the absolute amount of adipose tissue, as
has also been shown in humans (reviewed by ref. 36). The
importance of the adipose tissue expandability is further
supported by studies that have used thiazolidinediones
(TZDs) to treat NAFLD and NASH and reverse insulin
resistance in target tissues. These studies have demon-
strated good efficacy of TZDs to reduce lipid content in
the liver concordant with adipose tissue expansion37,38.
TZDs are potent PPARG agonists39 and thus, the pro-
posed role for PPARG as an inducer of steatosis in
hepatocytes appears conflicting with the efficacy of TDZs
in terms of reducing hepatic lipid content. On the other
hand, it is important to note that the main target tissues
for TDZs are adipose tissues and, as also suggested by
ref. 5, the expandability of the adipose tissue explains how
TDZs can be beneficiary for NASH since the increasing
capacity of adipose tissue to store fat allows repartitioning
of lipid from liver to adipose tissue. Since Göttingen
Minipigs are able to expand the fat compartments without
compromising adipose tissue metabolism it might be
hypothesized that naturally occurring fatty acids activate
PPARG in the liver of the FFC diet treated pigs,
mimicking treatments with TDZs, resulting in reparti-
tioning of lipid from liver to adipose tissues. Our findings
are in agreement with a previous study showing that
haplotypes segregating from Göttingen Minipigs can
uphold a healthy lipid profile despite development of
obesity indicating they have a phenotype comparable to
the MHO phenotype in humans14.
In conclusion, our study shows that severly obese
Göttingen Minipigs have a large capacity for adipose tis-
sue expansion and are protected against many of the
metabolic and hepatic abnormalities associated with
obesity. The study lends support to the hypothesis that
adipose tissue expandability and adaptation plays a crucial
role in the maintenance of metabolic homeostasis and
elucidates some of the molecular components underlying
the MHO-like phenotype in Göttingen Minipigs. In
contrast to what has been reported in human and mouse
studies, the highly significant upregulation of PPARG,
CD36, LPL, and FABP4 in the liver of the minipigs do not
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result in development of abundant hepatic steatosis. The
coordinated activation of lipid uptake and lipid bio-
synthesis by PPARG in the liver appears to be balanced by
the ability of the adipose tissues to expand and store
excessive calories. Although our study shed light on some
of the mechanisms that disassociate obesity from meta-
bolic complications a large number of questions, for
instance, regarding how adipose tissue plasticity is regu-
lated still remain. Identification of additional underlying
factors associated with the metabolic healthy obese phe-
notype in Göttingen Minipigs can contribute to a better
understanding of the factors that predispose, delay or
protect obese individuals from metabolic disturbances.
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